ORKA

Oruka Therapeutics Inc

80.06

Oct 21 • 3:57 PM ET +0.97 (1.23%)

Healthcare Biotechnology USA Mid NASD

Oct 20, 2:02 PMBroad biotech rally lifts Oruka nearly 7% intraday alongside psoriasis-focused peers Alumis and MoonLake

Peers: PTGX MLTX SYRE ALMS ARQT KYMR JBIO ACRS ATTO JNJ

| Held by: VTI XBI IWM VB VXF IWO IBB VBK VTWO SCHA

Scroll to Statements

Index	RUT
Market Cap	5.30B
Enterprise Value	4.43B
Income	-132.89M
Sales	0.00M
Book/sh	18.20
Cash/sh	13.19
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	68
IPO	Aug 08, 1997

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	4.40
P/C	6.07
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	38.51
Current Ratio	38.51
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-2.46
EPS next Y	-2.83
EPS next Q	-0.60
EPS this Y	-29.94%
EPS next Y	-17.62%
EPS next 5Y	-25.11%
EPS past 3/5Y	34.61% 37.79%
Sales past 3/5Y	- -
EPS Y/Y TTM	32.27%
Sales Y/Y TTM	-
EPS Q/Q	-12.26%
Sales Q/Q	-
Earnings	Aug 10 BMO
EPS/Sales Surpr.	-7.32% -

Insider Own	11.21%
Insider Trans	-34.98%
Inst Own	103.57%
Inst Trans	53.67%
ROA	-17.76%
ROE	-18.23%
ROIC	-11.90%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.27%
SMA50	-12.09%
SMA200	19.38%
Trades

Shs Outstand	61.07M
Shs Float	58.79M
Short Float	13.23%
Short Ratio	8.90
Short Interest	7.78M
52W High	115.51 -30.69%
52W Low	25.11 218.84%
Volatility	5.79% 5.42%
ATR (14)	4.25
RSI (14)	45.45
Beta	-0.30
Rel Volume	0.71
Avg Volume	874.17K
Volume	620,062

Perf Week	4.41%
Perf Month	-15.32%
Perf Quarter	-12.93%
Perf Half Y	14.90%
Perf YTD	164.14%
Perf Year	192.62%
Perf 3Y	511.09%
Perf 5Y	347.84%
Perf 10Y	-72.61%
Recom	1.07
Target Price	153.15
Prev Close	79.09
Price	80.06
Change %	1.23%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-25	Initiated	Piper Sandler	Overweight	$75
Nov-13-25	Initiated	Jefferies	Buy	$45
Oct-27-25	Initiated	Guggenheim	Buy	$60
Oct-13-25	Initiated	Barclays	Overweight	$48
May-22-25	Initiated	BTIG Research	Buy	$44
Feb-04-25	Initiated	Wolfe Research	Outperform	$20
Oct-11-24	Initiated	Stifel	Buy	$49
Oct-07-24	Initiated	H.C. Wainwright	Buy	$45
Sep-17-24	Initiated	Leerink Partners	Outperform	$44
Sep-16-24	Initiated	TD Cowen	Buy
Sep-13-24	Initiated	Jefferies	Buy	$40
Feb-27-18	Initiated	Ascendiant Capital Markets	Buy	$2
Oct-09-13	Initiated	Dawson James	Buy	$3.75

Show Previous Ratings

Sep-23-26 08:52AM	Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data (InvestorsHub)
07:00AM	Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing (GlobeNewswire)
Sep-09-26 04:01PM	Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-24-26 04:01PM	Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer (GlobeNewswire) -5.13%
Aug-10-26 07:03AM	Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +6.40%
07:26PM	Loading…
Jul-10-26 07:26PM	HMI Capital Pares Its Stake in AI Company nCino (Barrons.com)
May-28-26 08:00AM	Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-26 04:03PM	Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-26 05:07AM	Halozyme and Oruka sign agreement for Hypercon technology (Pharmaceutical Technology) -8.20%
Apr-28-26 07:42PM	Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering (GlobeNewswire) -7.96%
Apr-27-26 04:17PM	Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering (GlobeNewswire) +10.66%
10:24AM	Oruka Therapeutics psoriasis drug clears skin in 64% of patients (Quartz)
09:49AM	Oruka Therapeutics Shares Jump on Strong Psoriasis Trial Results (InvestorsHub)
08:12AM	Oruka surges as long-acting psoriasis drug shows early promise (BioPharma Dive)
07:01AM	How A Small Biotech Name Just Rattled AbbVie's $18 Billion Franchise (Investor's Business Daily)
07:00AM	Loading…
07:00AM	Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
Apr-26-26 12:00PM	Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026 (GlobeNewswire)
Apr-10-26 05:28PM	This Startup's Psoriasis Drug Studies Have Lifted Its Stock (Barrons.com) -6.32%
Mar-12-26 04:05PM	Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -7.03% +25.04%
Feb-09-26 07:00AM	Oruka Therapeutics to Participate in Multiple Upcoming Conferences (GlobeNewswire)
Jan-12-26 07:00AM	Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 (GlobeNewswire) +10.16%
Jan-06-26 07:00AM	Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 04:01PM	Oruka Therapeutics Announces New Board Member and Board Transition (GlobeNewswire)
Nov-12-25 04:05PM	Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -6.78%
Oct-29-25 09:55AM	Wall Street Analysts Predict a 63.59% Upside in Oruka Therapeutics, Inc. (ORKA): Here's What You Should Know (Zacks)
07:00AM	Oruka Therapeutics to Present at Multiple November Investor Conferences (GlobeNewswire)
Oct-13-25 05:52AM	Barclays initiates coverage on U.S. small & mid-cap biotech stocks (Investing.com)
Sep-29-25 04:24PM	MoonLake Crashes 90% On Mixed Results For Skin Disease Treatment (Investor's Business Daily) +26.91%
Sep-17-25 04:11PM	Oruka Therapeutics, Up 9%, Is Trying To Take On AbbVie's Biggest Moneymaker (Investor's Business Daily) +8.79%
01:02AM	Oruka Therapeutics Announces $180 Million Private Placement (GlobeNewswire)
01:00AM	Loading…
01:00AM	Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 (GlobeNewswire)
Aug-11-25 04:04PM	Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +6.90%
Jul-21-25 07:00AM	Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September (GlobeNewswire) -5.30%
Jul-01-25 04:01PM	Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer (GlobeNewswire) +5.26% +6.86%
May-27-25 03:32PM	H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial (Insider Monkey)
May-21-25 07:00AM	Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 04:01PM	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody (GlobeNewswire)
May-14-25 04:15PM	Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-25 07:00AM	Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference (GlobeNewswire)
Mar-07-25 08:30AM	Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-06-25 04:09PM	Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-19-25 07:00AM	Oruka Therapeutics to Present at Multiple March Investor Conferences (GlobeNewswire)
Dec-20-24 07:15AM	Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001 (TipRanks)
Dec-19-24 07:00AM	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody (GlobeNewswire)
Dec-18-24 07:00AM	Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) (GlobeNewswire)
Nov-19-24 08:00AM	Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference (GlobeNewswire) +5.54%
Nov-13-24 04:25PM	Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -6.43%
Nov-04-24 07:00AM	Oruka Therapeutics to Present at Multiple November Investor Conferences (GlobeNewswire)
Sep-25-24 07:08AM	Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-12-24 07:05AM	Oruka Therapeutics Announces $200 Million Private Placement (GlobeNewswire) -12.22%
07:00AM	Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001's Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19 (GlobeNewswire)
Sep-03-24 07:00AM	Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million (GlobeNewswire) -11.46%
Aug-29-24 04:50PM	ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split (GlobeNewswire) +33.19%
Aug-26-24 07:30PM	ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) -8.41%
Aug-23-24 04:30PM	ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) +6.12%
Aug-16-24 04:15PM	ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) +21.36%
Aug-01-24 04:15PM	ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +5.07%
Jun-28-24 02:16AM	Why Are Hedge Funds Shorting ARCA Biopharma, Inc. (ABIO)? (Insider Monkey) +6.39%
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey)
May-14-24 01:48PM	3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally (InvestorPlace)
Apr-25-24 09:55PM	ABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024 (InvestorPlace)
04:15PM	ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-03-24 02:30PM	Why Is ARCA Biopharma (ABIO) Stock Up 85% Today? (InvestorPlace) +90.06%
12:00PM	Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details (Benzinga)
07:30AM	ARCA biopharma and Oruka Therapeutics Announce Merger Agreement (GlobeNewswire)
Feb-01-24 04:35PM	ARCA biopharma Announces 2023 Financial Results (GlobeNewswire)
Oct-18-23 04:25PM	ARCA biopharma Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Jul-21-23 04:25PM	ARCA biopharma Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-13-23 11:30AM	We're Not Very Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Apr-24-23 04:25PM	ARCA biopharma Announces First Quarter 2023 Financial Results (GlobeNewswire)
Feb-24-23 04:20PM	ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-03-23 10:19AM	Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation (Simply Wall St.)
Dec-19-22 04:05PM	James Flynn Joins ARCA biopharma Board of Directors (GlobeNewswire)
Nov-14-22 09:24AM	One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year (Simply Wall St.)
Oct-28-22 04:15PM	ARCA biopharma Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Aug-02-22 04:15PM	ARCA biopharma Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-18-22 06:14AM	Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-21-22 04:05PM	Jacob Ma-Weaver Joins ARCA biopharma Board of Directors (GlobeNewswire) +5.56%
May-05-22 04:15PM	ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review (GlobeNewswire) -5.79%
May-02-22 04:15PM	ARCA biopharma Announces First Quarter 2022 Financial Results (GlobeNewswire)
Apr-18-22 04:30PM	ARCA biopharma Establishes Special Committee of the Board of Directors (GlobeNewswire)
Apr-05-22 01:35AM	Albioma : Governance changes (GlobeNewswire)
Apr-01-22 07:09AM	ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study (Benzinga)
Mar-31-22 04:15PM	ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial (GlobeNewswire)
Mar-14-22 04:15PM	ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-07-22 04:30PM	Battalion Oil Corporation Announces Fourth Quarter and Full Year 2021 Financial and Operating Results (GlobeNewswire)
Feb-08-22 04:21AM	We're Keeping An Eye On ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Jan-04-22 08:30AM	Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2 (GlobeNewswire)
Dec-02-21 08:30AM	ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19 (GlobeNewswire)
Nov-20-21 07:01AM	ClearPoint Neuro (NASDAQ:CLPT) shareholders are still up 635% over 3 years despite pulling back 13% in the past week (Simply Wall St.)
Nov-09-21 04:15PM	ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th (GlobeNewswire)
Nov-02-21 04:15PM	ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-21 07:03AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:26AM	ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged (Benzinga)
Oct-28-21 04:30PM	ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data (GlobeNewswire)
Sep-16-21 08:30AM	ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 (GlobeNewswire)
Aug-16-21 08:05AM	ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th (GlobeNewswire) -5.14%
Aug-12-21 01:15AM	We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-09-21 08:00AM	ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2 (GlobeNewswire)
Aug-04-21 04:15PM	ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +5.44%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Quinlan Paul T	General Counsel	Oct 20 '26	Option Exercise	7.80	9,000	70,200	38,995	Oct 20 08:42 PM
Quinlan Paul T	General Counsel	Oct 20 '26	Sale	78.53	9,000	706,735	29,995	Oct 20 08:42 PM
Goncalves Joana	Chief Medical Officer	Oct 15 '26	Option Exercise	7.32	7,000	51,240	38,771	Oct 15 06:15 PM
Goncalves Joana	Chief Medical Officer	Oct 15 '26	Sale	74.81	7,000	523,648	31,771	Oct 15 06:15 PM
JOANA GONCALVES	Officer	Oct 15 '26	Proposed Sale	76.68	21,000	1,610,280		Oct 15 04:38 PM
Agarwal Arjun	Senior Vice President, Finance	Oct 12 '26	Option Exercise	15.69	9,999	156,903	24,218	Oct 13 04:34 PM
Agarwal Arjun	Senior Vice President, Finance	Oct 12 '26	Sale	80.60	9,999	805,889	14,219	Oct 13 04:34 PM
Arjun Agarwal	Officer	Oct 12 '26	Proposed Sale	82.11	9,999	821,018		Oct 13 08:24 AM
Klein Lawrence Otto	Chief Executive Officer	Oct 01 '26	Option Exercise	7.80	25,000	195,000	948,128	Oct 02 07:54 PM
Klein Lawrence Otto	Chief Executive Officer	Oct 01 '26	Sale	83.62	25,000	2,090,593	923,128	Oct 02 07:54 PM
LAWRENCE KLEIN	Director	Oct 01 '26	Proposed Sale	83.29	25,000	2,082,250		Oct 01 04:22 PM
Agarwal Arjun	Senior Vice President, Finance	Sep 21 '26	Sale	95.75	533	51,035	14,219	Sep 21 05:38 PM
Quinlan Paul T	General Counsel	Sep 21 '26	Option Exercise	7.80	10,000	78,000	39,995	Sep 21 04:57 PM
Quinlan Paul T	General Counsel	Sep 21 '26	Sale	93.64	10,000	936,417	29,995	Sep 21 04:57 PM
Arjun Agarwal	Officer	Sep 21 '26	Proposed Sale	94.96	533	50,614		Sep 21 04:27 PM
Goncalves Joana	Chief Medical Officer	Sep 15 '26	Option Exercise	7.32	7,000	51,240	39,718	Sep 15 07:18 PM
Goncalves Joana	Chief Medical Officer	Sep 15 '26	Sale	92.38	7,947	734,145	31,771	Sep 15 07:18 PM
Agarwal Arjun	Senior Vice President, Finance	Sep 11 '26	Option Exercise	15.88	9,459	150,175	24,771	Sep 15 07:17 PM
Agarwal Arjun	Senior Vice President, Finance	Sep 11 '26	Sale	92.23	9,459	872,412	15,312	Sep 15 07:17 PM
Agarwal Arjun	Senior Vice President, Finance	Sep 15 '26	Sale	95.71	560	53,598	14,752	Sep 15 07:17 PM
Klein Lawrence Otto	Chief Executive Officer	Sep 15 '26	Sale	95.71	2,452	234,681	923,128	Sep 15 07:15 PM
Quinlan Paul T	General Counsel	Sep 15 '26	Sale	95.71	1,039	99,443	29,995	Sep 15 07:14 PM
Sandler Laura Lee	Chief Operating Officer	Sep 15 '26	Sale	95.71	906	86,713	235,478	Sep 15 07:11 PM
Sandler Laura Lee	Chief Operating Officer	Sep 01 '26	Option Exercise	7.80	5,000	39,000	241,384	Sep 01 06:36 PM
Sandler Laura Lee	Chief Operating Officer	Sep 01 '26	Sale	91.82	5,000	459,101	236,384	Sep 01 06:36 PM
Klein Lawrence Otto	Chief Executive Officer	Sep 01 '26	Option Exercise	7.80	75,000	585,000	1,000,580	Sep 01 06:35 PM
Klein Lawrence Otto	Chief Executive Officer	Sep 01 '26	Sale	91.83	75,000	6,887,484	925,580	Sep 01 06:35 PM
LAURA SANDLER	Officer	Sep 01 '26	Proposed Sale	92.62	5,000	463,100		Sep 01 04:50 PM
LAWRENCE KLEIN	Director	Sep 01 '26	Proposed Sale	92.62	75,000	6,946,500		Sep 01 04:48 PM
Goncalves Joana	Chief Medical Officer	Aug 17 '26	Option Exercise	7.32	7,000	51,240	39,718	Aug 17 06:09 PM
Goncalves Joana	Chief Medical Officer	Aug 17 '26	Sale	111.84	7,000	782,882	32,718	Aug 17 06:09 PM
Quinlan Paul T	General Counsel	Aug 14 '26	Option Exercise	11.60	52,000	603,000	83,034	Aug 14 05:52 PM
Quinlan Paul T	General Counsel	Aug 14 '26	Sale	108.49	52,000	5,641,409	31,034	Aug 14 05:52 PM
Agarwal Arjun	Senior Vice President, Finance	Aug 13 '26	Option Exercise	15.69	10,000	156,916	25,312	Aug 14 05:42 PM
Agarwal Arjun	Senior Vice President, Finance	Aug 13 '26	Sale	106.66	10,000	1,066,572	15,312	Aug 14 05:42 PM
PAUL QUINLAN	Officer	Aug 14 '26	Proposed Sale	108.12	71,000	7,676,520		Aug 14 04:39 PM
Goncalves Joana	Chief Medical Officer	Jul 15 '26	Option Exercise	7.32	7,000	51,240	39,718	Jul 15 07:36 PM
Goncalves Joana	Chief Medical Officer	Jul 15 '26	Sale	86.28	7,000	603,938	32,718	Jul 15 07:36 PM
JOANA GONCALVES	Officer	Jul 15 '26	Proposed Sale	87.47	21,000	1,836,870		Jul 15 04:31 PM
Agarwal Arjun	Senior Vice President, Finance	Jul 13 '26	Option Exercise	15.69	9,999	156,903	25,311	Jul 13 05:09 PM
Agarwal Arjun	Senior Vice President, Finance	Jul 13 '26	Sale	84.63	9,999	846,180	15,312	Jul 13 05:09 PM
Arjun Agarwal	Officer	Jul 13 '26	Proposed Sale	86.79	28,588	2,481,153		Jul 13 04:36 PM
Fairmount Healthcare Fund II L	Director, 10% Stockholder	Jul 01 '26	Proposed Sale	84.43	3,553,410	300,014,406		Jul 01 09:31 PM
Fairmount Funds Management LLC	Director	Jul 01 '26	Sale	84.43	3,553,410	300,014,406	1,131,954	Jul 01 09:30 PM
Sandler Laura Lee	Chief Operating Officer	Jul 01 '26	Option Exercise	7.80	5,000	39,000	241,384	Jul 01 07:58 PM
Sandler Laura Lee	Chief Operating Officer	Jul 01 '26	Sale	94.42	5,000	472,079	236,384	Jul 01 07:58 PM
Agarwal Arjun	Senior Vice President, Finance	Jun 22 '26	Sale	80.95	1,587	128,468	15,312	Jun 22 07:59 PM
Agarwal Arjun	Senior Vice President, Finance	Jun 12 '26	Option Exercise	15.88	9,459	150,175	26,753	Jun 15 06:57 PM
Agarwal Arjun	Senior Vice President, Finance	Jun 12 '26	Sale	69.72	9,459	659,508	17,294	Jun 15 06:57 PM
Agarwal Arjun	Senior Vice President, Finance	Jun 15 '26	Sale	69.69	395	27,528	16,899	Jun 15 06:57 PM
Goncalves Joana	Chief Medical Officer	Jun 15 '26	Option Exercise	7.32	7,000	51,240	40,665	Jun 15 06:54 PM
Goncalves Joana	Chief Medical Officer	Jun 15 '26	Sale	69.28	7,947	550,607	32,718	Jun 15 06:54 PM
Klein Lawrence Otto	Chief Executive Officer	Jun 15 '26	Sale	69.69	1,729	120,494	925,580	Jun 15 06:52 PM
Sandler Laura Lee	Chief Operating Officer	Jun 15 '26	Sale	69.69	600	41,814	236,384	Jun 15 06:51 PM
Quinlan Paul T	General Counsel	Jun 15 '26	Sale	69.69	733	51,083	31,034	Jun 15 06:50 PM
Dambkowski Carl	Director	Jun 11 '26	Sale	70.13	22,417	1,572,201	51,326	Jun 12 04:36 PM
Dambkowski Carl	Director	Jun 12 '26	Sale	70.11	12,583	882,182	38,743	Jun 12 04:36 PM
CARL DAMBKOWSKI	Director	Jun 11 '26	Proposed Sale	64.03	35,000	2,241,050		Jun 11 04:24 PM
Dambkowski Carl	Director	May 21 '26	Option Exercise	7.95	62,260	494,805	178,743	May 22 04:54 PM
Dambkowski Carl	Director	May 21 '26	Sale	58.97	105,000	6,191,366	73,743	May 22 04:54 PM
CARL DAMBKOWSKI	Director	May 21 '26	Proposed Sale	60.67	105,000	6,370,350		May 21 04:32 PM
Agarwal Arjun	Senior Vice President, Finance	May 18 '26	Option Exercise	28.80	7,833	225,597	26,696	May 18 06:07 PM
Agarwal Arjun	Senior Vice President, Finance	May 18 '26	Sale	59.07	10,290	607,806	16,406	May 18 06:07 PM
ARJUN AGARWAL	Officer	May 18 '26	Proposed Sale	61.93	22,206	1,375,218		May 18 04:34 PM
Goncalves Joana	Chief Medical Officer	May 15 '26	Option Exercise	7.32	7,000	51,240	40,377	May 15 08:17 PM
Goncalves Joana	Chief Medical Officer	May 15 '26	Sale	61.85	7,000	432,935	33,377	May 15 08:17 PM
Sandler Laura Lee	Chief Operating Officer	May 01 '26	Option Exercise	7.80	5,000	39,000	241,984	May 01 06:25 PM
Sandler Laura Lee	Chief Operating Officer	May 01 '26	Sale	63.88	5,000	319,384	236,984	May 01 06:25 PM
LAURA SANDLER	Officer	May 01 '26	Proposed Sale	68.41	10,000	684,100		May 01 04:42 PM
Goncalves Joana	Chief Medical Officer	Apr 15 '26	Option Exercise	7.32	7,000	51,240	40,377	Apr 15 06:45 PM
Goncalves Joana	Chief Medical Officer	Apr 15 '26	Sale	66.12	7,000	462,830	33,377	Apr 15 06:45 PM
JOANA GONCALVES	Officer	Apr 15 '26	Proposed Sale	67.06	21,000	1,408,260		Apr 15 04:54 PM
Klein Lawrence Otto	Chief Executive Officer	Mar 16 '26	Sale	41.30	1,729	71,408	927,309	Mar 17 04:10 PM
Agarwal Arjun	Senior Vice President, Finance	Mar 16 '26	Sale	41.30	395	16,313	18,863	Mar 17 04:09 PM
Sandler Laura Lee	Chief Operating Officer	Mar 16 '26	Sale	41.30	600	24,780	236,984	Mar 17 04:08 PM
Goncalves Joana	Chief Medical Officer	Mar 16 '26	Option Exercise	7.32	7,000	51,240	41,018	Mar 17 04:06 PM
Goncalves Joana	Chief Medical Officer	Mar 16 '26	Sale	40.91	7,641	312,560	33,377	Mar 17 04:06 PM
Quinlan Paul T	General Counsel	Mar 16 '26	Sale	41.30	733	30,273	31,767	Mar 17 04:04 PM
Sandler Laura Lee	Chief Operating Officer	Mar 02 '26	Option Exercise	7.80	5,000	39,000	242,584	Mar 02 06:47 PM
Sandler Laura Lee	Chief Operating Officer	Mar 02 '26	Sale	33.56	5,000	167,822	237,584	Mar 02 06:47 PM
Goncalves Joana	Chief Medical Officer	Feb 17 '26	Option Exercise	7.32	7,000	51,240	41,018	Feb 17 05:24 PM
Goncalves Joana	Chief Medical Officer	Feb 17 '26	Sale	32.37	7,000	226,559	34,018	Feb 17 05:24 PM
Goncalves Joana	Chief Medical Officer	Jan 15 '26	Option Exercise	7.32	7,000	51,240	8,518	Jan 16 05:26 PM
Goncalves Joana	Chief Medical Officer	Jan 15 '26	Sale	31.81	7,000	222,704	1,518	Jan 16 05:26 PM
Sandler Laura Lee	Chief Operating Officer	Jan 02 '26	Option Exercise	7.80	5,000	39,000	218,084	Jan 02 08:25 PM
Sandler Laura Lee	Chief Operating Officer	Jan 02 '26	Sale	28.52	13,000	370,795	205,084	Jan 02 08:25 PM
LAURA SANDLER	Officer	Jan 02 '26	Proposed Sale	30.31	18,000	545,580		Jan 02 04:31 PM
Goncalves Joana	Chief Medical Officer	Dec 19 '25	Option Exercise	7.32	7,000	51,240	8,518	Dec 19 05:38 PM
Goncalves Joana	Chief Medical Officer	Dec 19 '25	Sale	30.61	7,000	214,293	1,518	Dec 19 05:38 PM
JOANA GONCALVES	Officer	Dec 19 '25	Proposed Sale	28.15	28,000	788,200		Dec 19 04:20 PM

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

PresidentDr. Lawrence Otto Klein Ph.D.

General Counsel & SecretaryMr. Paul T. Quinlan

Chief Medical OfficerDr. Joana Goncalves M.D.

Senior VP of Finance & TreasurerMr. Arjun Agarwal CPA

Chief Operating OfficerMs. Laura Sandler

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ORKA

Oruka Therapeutics Inc

Upgrade your Finviz experience